Navigation Links
Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Date:5/23/2008

Novel Catheter Ablation System also delivers remarkably shorter procedure

times

CARLSBAD, Calif., May 23 /PRNewswire/ -- Ablation Frontiers, Inc. today announced that four presentations at the Heart Rhythm Society's 2008 Scientific Sessions reported positive early results using its novel Catheter Ablation System, and that these findings aligned well with each other and supported previous experience from the field.

The company's innovative multi-electrode mapping and ablation catheters used in conjunction with its duty-cycled radiofrequency (RF) generator were the subject of four presentations (AB9-3, AB9-5, PO5-17, and PO6-32). Three of these reports examined early outcomes using the advanced ablation system to treat atrial fibrillation (AF) patients in commercial procedures throughout Europe, while the fourth presentation focused on the feasibility phase for a US-based clinical study.

"In more than 1,000 commercial cases in Europe our technology has been very safe, highly effective and reduced procedures to well under 2 hours. Our commercial experiences are nicely substantiated by the four presentations given at HRS," stated Keegan Harper, CEO of Ablation Frontiers, Inc. "The results presented also align well with each other, with a total of 230 patients showing no adverse events, approximately 80 percent efficacy, and average procedure times ranging from 85 to 129 minutes."

The largest study included 132 patients with paroxysmal AF and was presented by Dr. Lam Dang of the Klinik Im Park in Zurich, Switzerland. He reported a procedure time of 129 +/- 36 minutes with no device-related complications. At the time of presentation, 80 percent of patients with 6 month follow-up were free from AF and had discontinued drug therapy.

Dr. Lucas Boersma of St Antonius Hospital in Nieuwegein, The Netherlands presented two abstracts that studied 85 patients with paroxysmal AF who were treated with the Ablation Frontiers system. These presentations demonstrated a 100 percent acute success rate, no peri/post-procedure complications up to 7 days, and procedure time of 85 +/- 33 minutes. Of those patients monitored at the 6 month follow-up date, 83 percent were free of AF and off anti-arrhythmic drugs.

A smaller study of 20 patients with permanent AF was presented by Dr. Gregory Michaud, Director of the Center for the Advanced Management of Atrial Fibrillation at the Brigham and Women's Hospital in Boston. This data represented procedures performed by 12 first-time operators as part of the feasibility phase of a US clinical trial called TTOP-AF, or the Tailored Treatment of Permanent AF, which is currently enrolling patients. Dr. Michaud reported that 96 percent of patients experienced a procedural success rate with no complications reported. At 6 months follow up, 75 percent of patients were in sinus rhythm, free of AF. After receiving early data from this group of patients, the Food and Drug Administration (FDA) allowed commencement of the pivotal TTOP-AF trial in the US.

"These early reports are extremely promising," noted Dr. Boersma, "and we are hopeful that long-term data will maintain consistency with the results presented. As physicians, we are excited about the remarkably close alignment of these safety and efficacy outcomes, with greatly reduced procedure times, in both the paroxysmal and permanent AF populations."

Atrial Fibrillation is a common and devastating cardiac rhythm disorder in which the heart's upper chambers beat in an extremely fast and chaotic rhythm. Symptoms may include palpitations, dizziness and shortness of breath. AF can present in different forms including paroxysmal, in which the abnormal rhythm starts and stops on its own, or permanent, which does not stop on its own and cannot be stopped with currently available medical treatments (drugs or cardioversion). Left untreated, AF patients are at an increased risk for stroke and may also develop heart failure or other cardiac disorders.

About Ablation Frontiers

Ablation Frontiers is an emerging, venture-backed medical device company based in Carlsbad, California. The company received $21.8 million Series C financing in June 2007, led by the Novartis Venture Fund, to drive clinical development and market expansion for their novel Cardiac Ablation System. Founded in 2004, Ablation Frontiers is dedicated to helping individuals suffering from atrial fibrillation and other cardiac arrhythmias. Working in concert with clinical experts in the field of ablation, the company is focused on developing and commercializing innovative products designed to make ablation procedures safer and less time consuming thereby making it possible for more individuals to benefit from this life-bettering therapy. In late 2006, Ablation Frontiers received the CE Mark to begin marketing in the European Union with its portfolio of anatomical-based catheters and a multi-channel RF generator. To learn more about the company, visit http://www.ablationfrontiers.com.


'/>"/>
SOURCE Ablation Frontiers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
2. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
3. IDM Pharma Announces Upcoming Clinical Data Presentations
4. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... ... that adult use in states where cannabis is legal will generate ... $559 million will be from cannabis specific taxes, such as ... remaining $96 million will be earned from state sales taxes that ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
(Date:3/27/2017)... , March 27, 2017  BERG, ... a data-driven, biological research approach, today announced ... to the discovery of new data using ... facilitate brown fat metabolism. Joslin Diabetes Center ... Interrogative Biology® platform for analysis of samples.  ...
Breaking Medicine Technology:
(Date:3/28/2017)... Mateo, CA (PRWEB) , ... ... ... Society (RSS), a non-profit medical society dedicated to advancing the science and ... leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry established ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 , ... ... and Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak ... have written to President Trump in support of an independent vaccine safety commission. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process ... in power plant water and steam. , Chlorides and sulfates cause pitting and ... to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... desire to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) ... what dentists should be aware of when utilizing dental laboratories and technicians that ...
Breaking Medicine News(10 mins):